Merck & Company, Inc. stock stays bullish as melanoma vaccine trial clears Phase 3

Merck & Company, Inc. stock shows a clear split between timeframes. The daily chart remains firmly bullish, while shorter timeframes reveal cooling momentum. Fresh clinical news from the Merck-Moderna melanoma vaccine program adds another layer. Trend and timing must now be read separately.

Key takeaways

• Merck & Company, Inc. stock closed at 135.17, with the daily EMA20/EMA50/EMA200 stack in classic bullish alignment.
• Daily RSI14 at 65.81 and a positive MACD histogram of 0.44 confirm momentum is still expanding to the upside.
• Hourly RSI14 has cooled to 50.99 and the 1H MACD histogram turned negative (-0.27), signaling short-term hesitation.
• The Phase 3 INTerpath-001 melanoma vaccine trial met its primary endpoints, driving shares in both Merck and Moderna higher.
• Price is boxed in a tight range near the daily pivot at 136.01, with S1 at 134.04 and R1 at 137.14.

Daily Trend: Bulls Still in Control of Merck Stock

The daily trend for Merck & Company, Inc. stock remains firmly bullish. The EMA20 at 131.06, EMA50 at 126.90, and EMA200 at 114.28 are stacked in classic uptrend order. This alignment signals a market where dips continue to attract buyers on a multi-month view.

… Continue reading the full article at the original source below.